SC Engineering

에쓰씨엔지니어링 · 023960

Industrials Construction & Engineering · KOSPI

Small-cap

Market cap US$25.9M (₩35.8B)

Overview

SC Engineering builds industrial plants, the large-scale facilities used to manufacture chemicals, pharmaceuticals, food products, and biochemicals, for clients across those industries.

It holds Korean government licences for industrial-environmental plant construction and civil-architectural construction, and delivers projects on a full turnkey basis. Listed on KOSPI, Korea's main stock exchange, the company also operates a subsidiary, Cellontech, that develops and supplies bio-collagen-based medical materials, including an injectable knee-cartilage supplement called CartiZol.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$124.9M

▼ −4.2% YoY

Operating profit · FY2025

−US$3.6M

Turned to loss

Net income · FY2025

−US$3.4M

Turned to loss

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$98.5M(₩136B)	US$130.3M(₩179.9B)	US$124.9M(₩172.3B)
Operating profit	US$712.3K(₩982.9M)	US$4.8M(₩6.6B)	−US$3.6M(−₩5B)
Net income	−US$1.7M(−₩2.4B)	US$2.7M(₩3.7B)	−US$3.4M(−₩4.8B)

Revenue

FY2023US$98.5M
FY2024US$130.3M
FY2025US$124.9M

Operating profit

FY2023US$712.3K
FY2024US$4.8M
FY2025−US$3.6M

Net income

FY2023−US$1.7M
FY2024US$2.7M
FY2025−US$3.4M

Key ratios (FY2025)

ROE

-10.1%

Debt/Eq

188.8%

Op. margin

-2.9%

Net margin

-2.8%

Rev. YoY

▼ −4.2%

Why it matters

The company's subsidiary Cellontech is named in the filing as conducting bio R&D and manufacturing collagen-based therapeutic materials alongside the core plant-construction business.

Price charts coming soon

Interactive price history isn't here yet. Would you use it?